CDXS News and Press, Codexis Inc. From 11/05/21

Image source: The Motley Fool. Codexis Inc (NASDAQ: CDXS) Q3 2021 Earnings Call Nov 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Codexis Inc (CDXS) Q3 2021 Earnings Call Transcript

Codexis, Inc. (CDXS) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Stephanie Marks – Investor Relations John Nicols – President and Chief Executive Officer Ross – Chief Financial Officer Conference Call Participants Brandon Couillard &#...

Codexis (NASDAQ:CDXS): Q3 GAAP EPS of $0.03 beats by $0.12. Revenue of $36.77M (+99.9% Y/Y) beats by $8.25M. Press Release For further details see: Codexis EPS beats by $0.12, beats on revenue

Record Quarterly Total Revenue, Product Revenue and Product Gross Margin Reiterating Total Revenue Guidance of $98-103M; Raising Product Revenue Guidance to $63-66M REDWOOD CITY Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering...

Funding to accelerate MAI’s go-to-market strategy as the enzyme engineering phase nears completion Represents the second early-stage company investment enabled by the SynBio Innovation Accelerator REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc....

Codexis (NASDAQ:CDXS) and Nestlé Health Science announce the dosing of the first subject in a Phase 1 study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108 for exocrine pancreatic insufficiency. CDX-7108 is a lipase variant speci...

REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, announced today the dosing of...

Codexis Inc. (NASDAQ:CDXS) traded today at a new 52-week high of $34.45. This new high was reached on below average trading volume as 299,000 shares traded hands, while the average 30-day volume is approximately 887,000 shares. Codexis Inc is involved in the business of providing enzyme ...

Codexis Inc. (NASDAQ:CDXS) traded today at a new 52-week high of $33.20. So far today approximately 299,000 shares have been exchanged, as compared to an average 30-day volume of 866,000 shares. Codexis Inc. share prices have moved between a 52-week high of $33.20 and a 52-week low of $1...

REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2021 on Thursday, November 4, 2021, followi...